Late-breaking ADA 2026 abstract acceptances for DA-1726 spark MetaVia's premarket surge

 

• MetaVia announced on May 18 that three late-breaking abstracts (highly selective) were accepted for poster presentations at the ADA 2026 Scientific Sessions (June 5-8 in New Orleans).
• Abstracts cover higher-dose Phase 1 results for DA-1726 (GLP-1/glucagon dual agonist/oxyntomodulin analog) in obesity plus data on vanoglipel (GPR119 agonist) for cardiometabolic indications.
• Builds directly on prior positive Phase 1 data (e.g., 9.1% weight loss, glucose control, liver benefit, favorable safety from 48 mg cohort highlighted in May 14 Q1 update).
• Same-day HC Wainwright analyst Andrew Fein reiterated Buy rating with unchanged $20 price target (stock previously ~$1.10–1.40 range; implies substantial upside in obesity sector).
• Micro-cap biotech (market cap ~$5–7M post-reverse split) with low float prone to sharp moves on clinical visibility; retail/forum momentum likely amplified volume and gains in premarket on the 19th.
• No other discrete May 19 catalyst (e.g., new earnings, partnership, or regulatory update) identified; move extends May 18 news digestion and positive sentiment around differentiated obesity asset.

https://finviz.com/quote?t=MTVA&p=d